Izervay FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 18, 2025.
FDA Approved: Yes (First approved August 4, 2023)
Brand name: Izervay
Generic name: avacincaptad pegol
Dosage form: Intravitreal Solution
Company: Astellas Pharma US, Inc.
Treatment for: Geographic Atrophy
Izervay (avacincaptad pegol) is a complement C5 protein inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Geographic atrophy is the advanced stage of age-related macular degeneration (AMD). Regions of the retina where the cells atrophy sometimes look like a map, hence the term geographic atrophy.
- Scarring and vision loss associated with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is thought to be caused by overactivity of the complement system and the C5 protein.
- Izervay contains a drug called avacincaptad pegol which works by targeting C5 to decrease activity of the complement system and potentially slow the progression of geographic atrophy.
- Izervay is administered by intravitreal injection to each affected eye once monthly (approximately 28 ± 7 days) for up to 12 months.
- Warnings and precautions associated with Izervay include an increased risk of endophthalmitis and retinal detachments, neovascular AMD, and increased intraocular pressure (IOP). Patients are advised to seek immediate care from an ophthalmologist if post-injection the eye becomes red, sensitive to light, painful, or if there is a change in vision.
- Common adverse reactions include conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
Development timeline for Izervay
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.